Journal of the Canadian Association of Gastroenterology最新文献

{"title":"A218 TRADING ONE PROBLEM FOR ANOTHER? THE EMERGENCE OF LYMPHOCYTIC ESOPHAGITIS IN A PEDIATRIC PATIENT WITH EOSINOPHILIC ESOPHAGITIS AFTER TREATMENT WITH DUPILUMAB","authors":"J. Strauss, M. Brundler, L. S. McKenzie","doi":"10.1093/jcag/gwad061.218","DOIUrl":"https://doi.org/10.1093/jcag/gwad061.218","url":null,"abstract":"Abstract Background Eosinophilic esophagitis (EoE) is a Th2 driven chronic, inflammatory disorder defined by esophageal dysfunction and a peak eosinophil count (PEC) ≧ 15 eosinophils/high-power field on biopsy. Dupilumab, a human monoclonal antibody that inhibits IL-4 and IL-13 signaling was recently approved for use in Canada in children with EoE. There is limited data on the histologic abnormalities found with reintroduction of dietary triggers on dupilumab. Aims To describe emergence of lymphocytic esophagitis without eosinophilia observed during food reintroduction in a pediatric patient with EoE on dupilumab. Methods Case report and literature review. Results We present a 14-year-old boy with extensive food allergies, eczema, asthma and treatment refractory EoE. After failing to improve with proton-pump inhibitor (PPI), food elimination diet and topical steroids, he was started on an elemental formula with concomitant PPI. This resulted in symptomatic and histologic remission, however food restriction led to poor quality of life. The patient was started on dupilumab 200 mg every 2 weeks and had a dramatic improvement in his disease course. Over 2 years on treatment, several allergic foods were reintroduced with normal histologic biopsies. However, two dietary challenges led to the emergence of lymphocytic esophagitis with basal zone hyperplasia (BZH) and dilated intercellular spaces (DIS), but no eosinophilia. Subsequent removal of the dietary antigen and endoscopic reassessment led to normal biopsies, without lymphocytic or eosinophilic infiltration. Lymphocytic esophagitis is rare in children and the etiology is unknown; it is characterized by increased intraepithelial lymphocytes without eosinophils or neutrophils, and associated spongiosis. The emergence of lymphocytic esophagitis was unexpected and subsequent normalization of histology with removal of an antigen suggests that the lymphocytic pattern observed was driven by the allergic food. This may indicate that IL-4/IL-13 antagonism by dupilumab affects other immune signaling pathways, resulting in a lymphocytic-predominant inflammatory response upon exposure to allergic food antigens. Conclusions Dupilumab is a promising new medication in the management of pediatric EoE, particularly in the extremely atopic patient. In our case, the use of dupilumab led to improved antigen tolerance and quality of life. However, the emergence of lymphocytic esophagitis was unexpected, and the natural history and prognosis of this condition is not well defined. This is the first case to describe the emergence of lymphocytic esophagitis in a patient treated for eosinophilic esophagitis with dupilumab, and its subsequent resolution with dietary exclusion. Funding Agencies None","PeriodicalId":508018,"journal":{"name":"Journal of the Canadian Association of Gastroenterology","volume":"6 11","pages":"173 - 173"},"PeriodicalIF":0.0,"publicationDate":"2024-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139837332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A71 IMPACT OF THE COVID-19 PANDEMIC ON WAIT TIMES, AND CLINICALLY RELEVANT FINDINGS AT COLONOSCOPY","authors":"A. Barkun, K. Ravanbakhsh, D Kim, G. Milky, P. Stanowski, O. Geraci, M. Martel, C. Menard, D. von Renteln","doi":"10.1093/jcag/gwad061.071","DOIUrl":"https://doi.org/10.1093/jcag/gwad061.071","url":null,"abstract":"Abstract Background The widespread use of a standardized and validated province-wide colonoscopy referral form (PCRF), regrouping mutually exclusive indications into suggested priority wait times categories (P1 to P5), has allowed for a more comprehensive description of routine colonoscopy practice. Aims To better understand the impact of COVID-19 on the routine practice of colonoscopy. Methods This is a multicenter retrospective cohort study of consecutive adult patients referred with PCRF data available from two Quebec tertiary hospitals. Patient and procedural characteristics were recorded. The primary outcomes were the diagnostic rates of colorectal cancers (CRC) and clinically significant lesions (CSF), defined as endoscopic findings affecting subsequent patient management, excluding hemorrhoids and diverticulosis. The secondary outcome was procedural wait times. We compared endpoints contrasting colonoscopy findings pre-COVID (before March 15th, 2020) to intra-COVID (after April 15th, 2020). Results 7,476 pre-COVID and 7,181 Intra-COVID patients (mean age 59.2 ± 14.0 years, 50.9% female) were included from 2018 to 2022. There were no clinically relevant between-group differences in patient characteristics. CRC detection remained similar (0.9% pre- vs 0.8% intra-COVID, p=0.69), while CSF were diagnosed more frequently intra-COVID (41,2% vs 39.7%, p=0.02). There were higher rates of indications performed for urgent and semi-elective priorities (P2, P3) intra-COVID (2.9% vs 1.3%, pampersand:003C0.01, and 50.5% vs 47.9%, pampersand:003C0.01). Corresponding intra- vs pre-COVID differences in indications (all Pampersand:003C0.01) included a clinical suspicion of active inflammatory bowel disease (6.4% vs 5.2%), a high index of suspicion for cancer based on imaging, endoscopy or clinical exam (2.9% vs 1.3%), suspicion of occult colorectal cancer (1.4% vs 0.9%), and doing a repeat endoscopy because of a prior inadequate bowel preparation (1.3% vs 0.8%). In contradistinction, more elective colonoscopies had been performed pre-COVID (P4: 15.5% vs 8.6%, pampersand:003C0.01, and P5: 5.2% vs 3.8%, pampersand:003C0.01. COVID Colonoscopy wait times grew significantly longer intra- vs pre-COVID (176.3 ± 252.4 days vs 78.6 ± 110.2 days, pampersand:003C0.01). Conclusions We witnessed significant changes in indications and referral priorities distributions for colonoscopy pre- vs intra-COVID, amidst longer wait times. These practice modifications did not alter CRC diagnostic yields, but resulted in greater proportions of CSF detection Funding Agencies CPAC and MSSS","PeriodicalId":508018,"journal":{"name":"Journal of the Canadian Association of Gastroenterology","volume":"156 ","pages":"48 - 49"},"PeriodicalIF":0.0,"publicationDate":"2024-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139837371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A22 INVESTIGATING THE EFFECTS OF DIET TRIGGER DISCLOSURE ON BEHAVIOUR IN IRRITABLE BOWEL SYNDROME (IBS) PATIENTS WITH PERCEIVED GLUTEN SENSITIVITY","authors":"C. Seiler, G. Rueda, P. Miranda, A. Nardelli, R. Borojevic, A. Hann, C. Southward, S. Rahmani, R. De Souza, A. Caminero, D. Schuppan, P. Moayyedi, Eduardo Verdu, S Collins, M. Pinto-Sanchez, P. Bercik","doi":"10.1093/jcag/gwad061.022","DOIUrl":"https://doi.org/10.1093/jcag/gwad061.022","url":null,"abstract":"Abstract Background Patients with self-perceived gluten sensitivity often undergo double-blinded, placebo-controlled (DBPC) challenge studies to determine whether gluten or wheat trigger their symptoms. However, it is unknown whether the result disclosure impacts patients’ beliefs and dietary choices. Aims To evaluate the impact of disclosing results of DBPC challenge with gluten and wheat on beliefs and dietary choices in IBS patients who adopt a gluten-free diet (GFD). Methods We conducted a DBPC crossover trial in 28 adult IBS patients (Rome IV) who previously reported improvement of symptoms while on a GFD. Patients were on a GFD throughout the study and were challenged for 7 days with whole wheat, purified gluten, and nocebo (gluten-free flour) added to low-FODMAP cereal bars, followed by 2-week washouts. Genetic predisposition to celiac disease and anti-gliadin IgG (AGA) were assessed. At least 6 months after the study completion, patients were contacted to assess their current diet, dietary beliefs, and symptoms prior to disclosing their study results. We assessed the same outcomes one month later. Statistical comparisons used paired Wilcoxon signed rank tests. Results The DBPC study showed similar proportions of participants reacting to wheat, gluten, and nocebo challenge, with greater symptoms after wheat compared to baseline (P<0.05). AGA IgG were present in 8% (2/25) and celiac disease-related genes in 80% (20/25) of patients. Out of 28 participants, 26 completed the pre-disclosure and 25 completed post-disclosure follow-up. All participants (N=26) believed that at least one challenge triggered their symptoms: whole wheat N=22, pure gluten N=23, nocebo N=2. Prior to disclosure, 17 participants continued while 9 abandoned the GFD; none changed their diet post-disclosure. Reasons to stay on the GFD included belief in its efficacy (N=16) and better quality of life (N=15), while reasons for abandoning included difficulty to adhere to the GFD and its cost (N=6) and losing belief in its efficacy (N=3). IBS symptoms did not change pre- vs. post-disclosure. Participants not reacting to wheat or gluten challenge expressed slightly lower median belief in GFD efficacy pre- vs. post-disclosure (80%, IQR [64%, 97%] vs 71%, IQR [48%, 78%]; P=0.03; Figure 1). Those worsening after wheat or gluten did not change their beliefs. Conclusions Although most IBS patients with self-perceived gluten sensitivity had celiac disease predisposition, only some reacted to gluten or wheat. Furthermore, after disclosing the study results, all participants maintained their dietary habits avoiding gluten, thus suggestive of strong central mechanisms underlying their symptoms. Figure 1. Belief in GFD efficacy pre- vs. post-disclosure of study results. Funding Agencies CIHRSociety for the Study of Celiac Disease, Nestle","PeriodicalId":508018,"journal":{"name":"Journal of the Canadian Association of Gastroenterology","volume":"107 ","pages":"12 - 13"},"PeriodicalIF":0.0,"publicationDate":"2024-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139837442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A31 DYSPLASIA IN COLONIC POLYPS: PREPARING FOR A RESECT AND DISCARD STRATEGY IN CANADA","authors":"V Patel, R. Bechara, M. S. Rai","doi":"10.1093/jcag/gwad061.031","DOIUrl":"https://doi.org/10.1093/jcag/gwad061.031","url":null,"abstract":"Abstract Background While diminutive colorectal polyps have a negligible cancer risk, current management involves resecting and submitting all polyps for histological assessment. This is a substantial burden and cost to the healthcare system. The European Society of Gastrointestinal Endoscopy (ESGE) has recommended a “resect-and-discard strategy” without histological evaluation as an acceptable strategy when high-confidence endoscopic characterization of colorectal polyps is achieved. However, a resect and discard strategy has not been adopted yet in Canada. Aims The objective of this study was to determine the prevalence and characteristics of polyps removed at our center based on size. Methods We retrospectively reviewed colonoscopies and pathology reports at Kingston Health Sciences Center from January to December 2020. Based on the pathology report, polyps were classified as diminutive (1-5mm), small (6-9mm) or large (ampersand:003E or = 10mm). We recorded histology and the presence of high-grade dysplasia (HGD) or cancer. Results Out of 2218 colonoscopies, 2945 polyps were removed. 1703 (57.8%) polyps were diminutive with only two (0.1%) having focal HGD and none having cancer. 699 (23.7%) polyps were classified as small with three (0.4%) having HGD and none having cancer. The large polyp group had 543 (18.4%) polyps, of which 87 (16%) showed HGD and 15 (2.8%) exhibited cancer. The specific histologic findings are shown in Table 1. Endoscopy reports specifically mentioned concern of dysplasia in one out of the five polyps with HGD in the diminutive and small groups. Conclusions As expected, most polyps were either diminutive or small (81.5%). Neither of these groups had cancer and only 5 had HGD. Adopting a resect and discard strategy at our center for diminutive polyps has the potential for significant cost savings with negligible risk of missing a high-risk polyp. The next steps would involve assessing optical diagnosis sensitivity and specificity for diminutive and small polyps. Histological characterization of polyps within each size range Histology Diminutive (1-5mm) Small (6-9mm) Large (≥10mm) Tubular adenoma 1212 (71.2%) 459 (65.7%) 274 (50.5%) Tubular adenoma with HGD 1 (0.1%) 2 (0.3%) 32 (5.9%) Hyperplastic 347 (20.4%) 100 (14.3%) 29 (5.3%) Sessile Serrated 107 (6.3%) 107 (15.3%) 73 (13.4%) Sessile Serrated with HGD 1 (0.1%) 0 4 (0.7%) Tubulovillous 19 (1.1%) 25 (3.6%) 77 (14.2%) Tubulovillous with HGD 0 1 (0.1%) 36 (6.6%) Inflammatory 16 (0.9%) 5 (0.7%) 3 (0.6%) Adenocarcinoma 0 0 15 (2.8%) Total 1703 699 543 Funding Agencies None","PeriodicalId":508018,"journal":{"name":"Journal of the Canadian Association of Gastroenterology","volume":"95 2","pages":"17 - 17"},"PeriodicalIF":0.0,"publicationDate":"2024-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139837557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A7 CANNABINOID 1 AND 2 RECEPTOR AGONISTS AND MU-OPIOID RECEPTOR AGONISTS SYNERGISTICALLY INHIBIT COLONIC NOCICEPTION DURING ACUTE COLITIS","authors":"Q. Tsang, A. Lomax, S. Vanner, D E Reed","doi":"10.1093/jcag/gwad061.007","DOIUrl":"https://doi.org/10.1093/jcag/gwad061.007","url":null,"abstract":"Abstract Background Abdominal pain is a debilitating symptom in patients with inflammatory bowel disease. Previously we have shown that combining sub-analgesic doses of cannabinoid 1 receptor (CB1R), but not cannabinoid 2 receptor (CB2R), and mu-opioid receptor (MOR) agonists synergistically inhibits colonic nociception in healthy mice. However, it is unknown whether this combination has analgesic efficacy in a pre-clinical model of colitis. Aims To determine the effects of combining sub-analgesic doses of CBR and MOR agonists on colonic nociception during acute colitis. Methods Colitis was induced in male and female C57BL/6 mice with 2.5% dextran sulfate sodium in drinking water. Extracellular afferent nerve recordings were obtained from ex vivo flat sheet preparations of mouse distal colon. Mechanosensitivity of single afferent axons was assessed via probing of the colon with a 1g von Frey hair before and after superfusion of agonists of CB1R or CB2R plus MOR. To examine effects in vivo, visceromotor response (VMR) to colorectal distention (volume range 20-80 µL) was measured via electromyography. Mice were injected intraperitoneally with vehicle, or a combination of CB1R or CB2R agonist plus morphine 30-minutes prior to VMR experiment. Data were analyzed using a one or two-way ANOVA with Bonferroni test. N denotes number of mice; n denotes number of single afferent axons. Results In afferent nerve recordings, in contrast to healthy mice, the CB2R agonist HU-308 (1 µM and 3 µM) inhibited colonic mechanosensitivity in mice with colitis (1 µM: p<0.01, N=5, n=12; 3 µM: p<0.01, N=7, n=10); a lower concentration (300 nM) had no effect (p=0.52, N=6, n=10). The CB1R agonist ACEA (10 µM) reduced mechanosensitivity during acute colitis (p<0.05, n=11, N=6), whereas 100 nM (p>0.99, n=7, N=5) and 1 µM (p=0.25, n=10, N=6) had no effect. A combination of sub-analgesic concentrations of ACEA (100 nM) and DAMGO (MOR agonist, 1 nM) inhibited colonic mechanosensitivity in healthy mice (p<0.01, N=4, n=8) and during acute colitis (p<0.05, N=6, n=8). While a combination of sub-analgesic concentrations of HU-308 (300 nM) and DAMGO (1 nM) had no effect in healthy mice (p=0.70, N=4, n=8), it inhibited colonic mechanosensitivity during acute colitis (p<0.01, N=8, n=15). In VMR experiments, a combination of a sub-analgesic dose of ACEA (0.3 mg/kg) with morphine (0.3 mg/kg) reduced VMR (p<0.01, N=7) during acute colitis. Similarly, a combination of a sub-analgesic dose of HU-308 (1 mg/kg) and morphine (0.3 mg/kg) reduced VMR (p<0.01, N=6) during acute colitis. Conclusions A CB2R agonist inhibits colonic nociception during acute colitis, but not in healthy mice. A sub-analgesic combination of CB1R and MOR agonists can inhibit pain in healthy and inflamed mice, while combining sub-analgesic CB2R and MOR agonists is only inhibitory during acute colitis. Funding Agencies NRC","PeriodicalId":508018,"journal":{"name":"Journal of the Canadian Association of Gastroenterology","volume":"47 2","pages":"4 - 5"},"PeriodicalIF":0.0,"publicationDate":"2024-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139837577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A21 EFFECTS OF LYOPHILIZED FECAL FILTRATE COMPARED TO LYOPHILIZED DONOR STOOL IN THE TREATMENT OF RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION: A MULTI-CENTER RANDOMIZED TRIAL","authors":"D. Kao, K Wong, C Lee, T. Steiner, R. Franz, C. McDougall, M Silva, M. Yaskina, J. Walter, V. Loo, R. Loebenberg, H Xu, T. Louie","doi":"10.1093/jcag/gwad061.021","DOIUrl":"https://doi.org/10.1093/jcag/gwad061.021","url":null,"abstract":"Abstract Background Fecal microbiota transplantation (FMT) is the most effective therapy in the treatment of recurrent Clostridioides difficile infection (rCDI), and can be offered in fresh, frozen or lyophilized formulation with similar efficacy. Microbial engraftment is thought to be one of the mechanisms mediating its efficacy. However, the importance of microbes has been questioned by two small preliminary clinical studies that showed sterile fecal filtrate could prevent C. difficile recurrence. Aims To establish whether lyophilized sterile fecal filtrate (LSFF) is noninferior to lyophilized FMT (LFMT) in efficacy Methods In this double-blind, non-inferiority study conducted in 4 academic centers in Alberta and British Columbia, we randomized rCDI patients with ≥ 3 CDI episodes to either LSFF or LFMT at a 1:1 ratio between 2019 and 2023.The non inferiority margin was 10%. Each treatment dose consisted of 15 oral capsules. Participants who failed the assigned treatments were offered open-label LFMT. An interim analysis was planned after reaching 50% of recruitment target (124/248 participants). Primary outcome was the proportion of participants without CDI recurrence 8 weeks following assigned treatment. Secondary outcomes included 1) the proportion of participants without CDI recurrence 24 weeks following assigned treatment, 2) serious adverse events (mortality, hospitalization and infections related to treatments), and 3) minor adverse events (nausea, vomiting, abdominal pain and fever). Exploratory outcomes included changes in quality of life, stool microbial composition analyses, as well as patient preferences. Results 137 participants were randomized (mean [SD] age, 61.2 [18.6] years; 89 women [65.4%]; mean CDI episodes 3.8) to LFMT group (66 participants) and LSFF (71 participants) group. In per-protocol analysis, prevention of rCDI 8 weeks after assigned treatment was achieved in 63.8% of participants in LSFF group and 86.9% in LFMT group (difference, -23.1%), resulting in trial termination. Serious adverse events were infrequent: 4 hospitalizations deemed not related and 1 hospitalization possibly related, and 1 death from COVID deemed not related to assigned treatment. Minor adverse events were self-limited and infrequent: nausea (6), vomiting (2), abdominal discomfort (15) and fever (2). Conclusions Among adults with rCDI, LSFF was inferior to LFMT by oral capsules in preventing recurrent infection over 8 weeks. The result emphasizes the importance of microbes in mediating FMT efficacy. Preserving microbial viability in future development of microbial therapeutics is paramount. Funding Agencies CIHR","PeriodicalId":508018,"journal":{"name":"Journal of the Canadian Association of Gastroenterology","volume":"134 ","pages":"12 - 12"},"PeriodicalIF":0.0,"publicationDate":"2024-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139837894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A151 THRESHOLD TRANSFERABILITY STUDY FOR 3 QUANTITATIVE FITS IN AN ACTIVE COLORECTAL CANCER SCREENING PROGRAM (CRCSP)","authors":"J. Dube, R. Plantefève, C. Menard, M. Bonin, J. Rousseau, C. Francois, A. Caku","doi":"10.1093/jcag/gwad061.151","DOIUrl":"https://doi.org/10.1093/jcag/gwad061.151","url":null,"abstract":"Abstract Background Three quantitative fecal immunochemical tests (FITs) were evaluated in the context of a possible supplier transition of the Quebec CRCSP. FITs from different suppliers have different sensitivities, specificities and positivity rates at preset thresholds (PT) which impacts the number of colonoscopies generated. Our hypothesis was that the determination of an equivalent threshold (ET) by a positivity rate equivalent strategy (PRES) or with regression analysis would lead to similar clinical performances. Aims Determine if ETs can be obtained and what their impact is on the sensitivity and specificity of each supplier Methods Kits containing a collection tube for each supplier were distributed to 6600 patients. Sampling was done on a fresh stool by patients with specific instructions for each supplier. Patients with FIT results ≥35 ug/g of stool hemoglobin were considered positive and referred for a colonoscopy within the CRCSP and those between 20 and 35 ug/g were invited to consent to a colonoscopy. Colonoscopy results were considered positive if advanced neoplasia (AN) was found. ETs were determined by PRES and regression analysis comparing each pair of suppliers. Median sensitivity and specificities were computed for each supplier at current and ETs. Results Kits from 5513 patients were included in the study. Colonoscopy results were obtained for 262/342 FIT positive patients and 65/155 patients with results between 20 and 35 ug/g who consented to a colonoscopy. 69 patients were positive for AN at colonoscopy. ETs were obtained for the PRES but not for the regression method due to failed linearity tests. The ETs yielding the same positivity rate as Eiken’s 35.0 ug/g were determined to be 21.6 ug/g and 37.4 ug/g for Sentinel and Alfresa respectively. At the PT, the sensitivities of Alfresa (0.71, CI :0.58-0.80) and Eiken (0.71, CI:0.58-0.80) did not differ significantly but were higher than Sentinel (0.52, CI:0,39-0,64, p= 0.0059 and 0.016). The specificity for Sentinel (0.64, CI: 0.57-0.69) was significantly higher than Alfresa (0.45, CI: 0.38-0.50, p= 3.3E-6) and Eiken (0.54, CI: 0.47-0.59, p= 0.0059), as was the one from Eiken when compared to Alfresa (p =0.038). After adjustment using PRES, no significant differences for sensitivity (Alfresa (0.68, CI:0.55-0.77), Eiken (0.71, CI :0.58-0.80), Sentinel (0.52, CI:0.46-0.70)) and specificity (Alfresa (0.51 CI: 0.45-0.57), Eiken (0.54, CI: 0.47-0.59), Sentinel (0.57, CI: 0.50-0.62)) were observed between suppliers. Conclusions Our study demonstrates that a PRES can be used to adjust the threshold in a supplier transition in order to achieve similar clinical performances. To our knowledge this is the first study to evaluate this in a real life active CRCSP setting where the stool is sampled by the patient and non-homogenized. Funding Agencies Ministère de la Santé et des Services Sociaux du Québec and private funds (Somagen-Eiken, Quidel-Sentinel, Abbott-Alfresa)","PeriodicalId":508018,"journal":{"name":"Journal of the Canadian Association of Gastroenterology","volume":"112 ","pages":"116 - 117"},"PeriodicalIF":0.0,"publicationDate":"2024-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139837912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A182 EXPLORING THE LINK BETWEEN SPECIFIC MICROBIAL STRAINS AND ANXIETY AND DEPRESSION IN PATIENTS WITH ULCERATIVE COLITIS","authors":"B. A. Chiew, N. Haskey, A Lewis, H. Nadeem, S. L. Gold, L M Taylor, K. McCoy, C. Ohland, K. McGregor, M. Raman","doi":"10.1093/jcag/gwad061.182","DOIUrl":"https://doi.org/10.1093/jcag/gwad061.182","url":null,"abstract":"Abstract Background Anxiety and/or depression (A/D) have been identified as significant co-morbidities of ulcerative colitis (UC), and even considered as extraintestinal manifestations, with emerging evidence to support the role for gut microbial dysbiosis in the natural history for both UC and A/D. However, there is a paucity of knowledge regarding the specific attributes of the gut bacteriome in individuals with UC with concomitant A/D. Aims To explore the connection between the gut bacteriome and A/D in a cohort of patients with UC. Methods This cross-sectional study included 29 participants diagnosed with UC either in remission or with mild to severe disease. To test for depression and anxiety, participants completed the Patient Health Questionnaire-8 (PHQ-8) and General Anxiety Disorder-7 (GAD-7) respectively. Participants provided a stool sample for microbiome analysis and the fecal bacteriome was assessed using metagenomic shotgun sequencing. Results Among the 29 patients, 55% were female (n=16) and 45% were male (n=13), 34.5 % (n=10) had a Partial Mayo Score over 5 indicating moderate-severe disease activity (median 3, IQR 1-6). Mean age was 38.3 years (± 12.2 years). Sixty-nine percent were on 5-ASA, 42.9% on steroids, 31.0% on Anti-TNF, and 20.7% on immunomodulators. Mean FCP was 976.4 μg/g (± 1589.2). Forty-four percent (n=12) screened positive for anxiety with a median GAD-7 score of 5.0 (IQR: 1-8), while 26% screened positive for depression with a median PHQ-8 of 3 (IQR: 3-10). Principal Coordinate Analysis (PCoA) reveals distinct clustering between UC patients with or without A/D (Figure 1). Regarding the microbial analyses, the log fold change of Firmicutes bacterium CAG:424, Holdemanella biformis, Blautia hansenii, Bifidobacterium pullorum, Anaerostipes caccae, and Ruminococcus gnavus exhibited positive associations with both A/D, whereas Roseburia sp. CAG:303, Prevotella copri, and Bacteroides stercoris demonstrated negative associations. Uniquely, Faecalicoccus pleomorphus and Lachnospira pectinoschiza showed negative associations only with the PHQ-8. Conclusions Our research affirms the presence of anxiety and depression in a cohort of UC patients. The severity of A/D measured by the GAD-7 and PHQ-8 were linked to the levels of specific fecal microbes. We introduce several novel species that warrant further examination in UC patients with and without A/D. As this was an exploratory study, the findings need replication in a larger sample size. PCoA results reveal distinct bacterial clustering patterns between individuals with minimal anxiety/depression (absence) versus those with mild/moderate/severe anxiety and depression as measured by GAD-7 and PHQ-8. Funding Agencies None","PeriodicalId":508018,"journal":{"name":"Journal of the Canadian Association of Gastroenterology","volume":"69 ","pages":"143 - 144"},"PeriodicalIF":0.0,"publicationDate":"2024-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139838013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A294 CHOLESTASIS SECONDARY TO XANTHOGRANULOMATOUS CHOLANGITIS: A CASE REPORT","authors":"K. A. Labib, K. Bishay","doi":"10.1093/jcag/gwad061.294","DOIUrl":"https://doi.org/10.1093/jcag/gwad061.294","url":null,"abstract":"Abstract Background An 86-year-old female presented with four weeks of intermittent abdominal pain, postprandial nausea with an associated 10 lbs weight loss. Initial labs demonstrated a predominantly cholestatic liver enzyme elevation. Imaging revealed a thickened gallbladder with dilated CBD up to 15mm with no calculi, obstruction or pancreatic mass. EUS demonstrated a prominent ampulla with an area of hyperechogenicity, and ERCP was completed with sphincterotomy and biopsy of the ampulla. A cholangiogram showed a prominent common bile duct and a smooth distal taper without filling defects. Tumor markers, ampullary biopsy, and cytology of CBD brushings were negative for malignancy. Repeat ERCP for non-resolving symptoms with an extension of the sphincterotomy, brushings and insertion of a metal stent was completed without improvement in liver enzymes and a standard hepatitis workup returned negative. Her clinical course was further complicated by recurrent gram-negative bacteremia with CT findings of innumerable abscesses or metastasis in the liver. A US-guided targeted liver biopsy revealed large duct periductal tissue expansion by foamy macrophages with admixed neutrophils, eosinophils, plasma cells, and lymphocytes. These features were consistent with xanthogranulomatous cholangitis. We were planning to start ursodiol given the small duct disease however the patient succumbed to recurrent bacteremia and passed away. Aims Review of methods to attain diagnosis of xanthogranulomatous cholangitis. Methods Case Report. Results Diagnosis of xanthogranulomatous cholangitis can be attained from targetted US-guided biopsy, surgical excision, or EUS-guided CBD biopsy. Conclusions Xanthogranulomatous cholangitis is an extremely rare entity described in limited case reports, frequently mimicking neoplastic disease. Pathology is difficult to attain and historically case reports required surgical resections. One recent case reported diagnosis confirmed via EUS-guided FNA of the CBD. In our case, we attained the diagnosis through a targeted liver biopsy. Pathology of xanthogranulomatous cholangitis typically demonstrates foamy histiocytes, lipid-laden macrophages, eosinophils, lymphocytes, plasma cells, and fibrosis indicating xathogranulomas. The pathogenesis is thought to be an extension of xanthogranulomatous cholecystitis in which bile is extravasated into the gallbladder wall through Rokitansky-Aschoff sinuses or ulceration of the mucosa resulting in an inflammation caused by fibroblasts and macrophages as they phagocytose the lipids in bile, resulting in the formation of xanthoma cells. Given the rarity of the disease, there is no guideline on management and a majority of patients reported underwent surgical excision. This case demonstrates the utility of liver biopsy to establish this rare diagnosis, allowing for better detection and subsequently better-studied management. Funding Agencies None","PeriodicalId":508018,"journal":{"name":"Journal of the Canadian Association of Gastroenterology","volume":"54 ","pages":"238 - 239"},"PeriodicalIF":0.0,"publicationDate":"2024-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139838228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A113 COVID-19 VACCINATIONS IN IBD PATIENTS: PATIENT KNOWLEDGE AND PERCEPTIONS","authors":"A. Saunders, L Hill, D. Armstrong, J Marshall, N. Narula, N. Pai, U. Chauhan","doi":"10.1093/jcag/gwad061.113","DOIUrl":"https://doi.org/10.1093/jcag/gwad061.113","url":null,"abstract":"Abstract Background The IBD population has historically suffered from a below average uptake of vaccinations which raises concern for COVID-19 vaccine acceptance in this population. Patients report IBD-specific reasons for COVID-19 vaccine hesitancy including fear of vaccine-related IBD flare up, a desire for IBD-specific data regarding COVID-19 vaccine safety and efficacy, and worry about current drugs affecting vaccine efficacy. Additionally, IBD patients tend to report greater fear of COVID-19, concern about the impact of their medications on COVID-19 disease, and overall need for COVID-19 information. Aims To explore patients’ education, knowledge, and perceptions of COVID-19 vaccination with the aim of lowering COVID-19 vaccine hesitancy, improving knowledge of COVID-19 vaccines, and identifying outstanding barriers to COVID-19 vaccination uptake. Methods Study participants are patients diagnosed with IBD recruited from the Adult IBD Clinic at McMaster University Medical Centre between June 2022 and May 2023. Quantitative questionnaires were distributed to participants following receipt of informed consent at routine clinics and were offered in paper format. To describe the study population, the following descriptive statistics were performed: means and standard deviation for continuous variables, distributions (n, %) for dichotomous and categorical variables. Results In total, 236 participants were surveyed. The sample is predominantly female (61%) and most participants are diagnosed with Crohn’s disease (63.9%). The vast majority of patients have received at minimum 1 dose of a COVID-19 vaccine (92.1%). Reported reasons for vaccination included COVID-19 vaccine being available free of cost (52.3%), recommendation from a healthcare professional (51.9%), and feeling as though the benefit of the vaccine outweighs the risks (51.6%). Most patients reported having heard of negative vaccine experiences online (75.8%) including mild (27.6%) and severe (30.8%) adverse reactions. Despite this, participants viewed vaccines as effective (83%), protective towards the individual (75.5%), and safe (68.1%). Healthcare providers were regarded as a very significant influence in terms of COVID-19 vaccine information (65.6%) and were overwhelmingly viewed as a more reliable source than mass media (91.3%). Participants did not perceive an increased risk of COVID-19 infection, COVID-19 related serious illness, or COVID-19 vaccine related adverse effects due to their IBD or IBD treatments. Participants also did not show reluctance to vaccinate due to their IBD or IBD treatments. Conclusions The present study provides insight into the perceptions and knowledge of Canadian IBD patients as it relates to COVID-19 vaccines. Importantly, the results highlight the crucial role of the healthcare provider on vaccination uptake and acceptance. Funding Agencies None","PeriodicalId":508018,"journal":{"name":"Journal of the Canadian Association of Gastroenterology","volume":"57 3","pages":"85 - 85"},"PeriodicalIF":0.0,"publicationDate":"2024-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139838263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}